CT-011 + FOLFOX

CT-011 + FOLFOX is an investigational combination treatment regimen composed of the **monoclonal antibody CT-011** (which targets the immunological checkpoint receptor PD-1, also called PDCD1), and the established chemotherapy combination **FOLFOX**. FOLFOX itself comprises **folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin**. CT-011 blocks PD-1, thereby preventing immune evasion by tumor cells and enhancing T-cell mediated anti-tumor activity (a checkpoint inhibitor mechanism). FOLFOX acts as a cytotoxic regimen that disrupts DNA synthesis and function in rapidly dividing cancer cells. The combination is under investigation for synergistic effects in cancer therapy, particularly in gastrointestinal cancers, with a rationale that immunotherapy (CT-011) can improve the efficacy of chemotherapy (FOLFOX) by activating the immune system alongside direct cytotoxic activity.